18F-fluorodeoxyglucose (18FDG) PET pulmonary imaging in COPD Source: International Congress 2015 – CT, PET, MRI modalities: fusion of anatomical and functional variables for lung assessment Year: 2015
18F-fluorodeoxyglucose (18FDG) PET pulmonary imaging:comparative methodology in COPD patients Source: International Congress 2014 – COPD and PAH related imaging Year: 2014
(18)F-FDG positron emission tomography/computed tomography and pulmonary function in sarcoidosis Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013
Positron emission tomography (PET) using 18 F-fluorodeoxyglucose (18 FDG) can detect radiographically ”occult“ lung cancer (ROLC) in the central airways Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001
Quantitative 18 F-fluorodeoxyglucose positron emission tomography/computed tomography to assess pulmonary inflammation in COPD Source: ERJ Open Res, 7 (3) 00699-2020; 10.1183/23120541.00699-2020 Year: 2021
Increased FDG uptake on 18F-FDG PET/CT in residual lesions of tuberculosis Source: International Congress 2019 – Tuberculosis: from diagnosis to complications Year: 2019
The role of 18-FDG PET/CT in lung sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017
Imaging the inflammatory activity of sarcoidosis Source: Eur Respir J 2013; 41: 743-751 Year: 2013
CT and FDG PET/CT findings of pulmonary involvement in methotrexate-associated lymphoproliferative disease Source: International Congress 2018 – CC6 Interstitial lung diseases Year: 2018
18F-Fluorodeoxyglucose (18FDG) PET pulmonary imaging: Role in detecting vascular inflammation Source: International Congress 2015 – CT, PET, MRI modalities: fusion of anatomical and functional variables for lung assessment Year: 2015
The Value of 18F-FDG PET/CT in evaluating disease severity in idiopathic pulmonary fibrosis Source: International Congress 2017 – ILDs: clinical aspects Year: 2017
Use of integrated FDG PET/CT imaging in pulmonary cacinoid tumors Source: Eur Respir J 2006; 28: Suppl. 50, 775s Year: 2006
Positron emission tomography with 18F-fluoro-deoxyglucose (FDG-PET) for evaluation of indeterminate adrenal mass in patients with lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002
Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 227s Year: 2001
A comparison of fluorodeoxyglucose positron emission tomography (FDG-PET) and transthoracic needle biopsy (TNB) in the management of single pulmonary nodules (SPN) Source: Annual Congress 2004 - Pneumothorax, chest drains Year: 2004
Comparison of chest x-ray, thoracic computed tomography and 18F-FDG PET/CT for staging of sarcoidosis Source: International Congress 2015 – Sarcoidosis: clinical Year: 2015
Influence of acute smoking on pulmonary inflammatory cell activity measured by positron emission tomography (PET) in asymptomatic cigarette smokers Source: Annual Congress 2005 - New modalities and application in lung and airway imaging Year: 2005
Primary pulmonary artery sarcomas: improvement of preoperative diagnostic by positron emission tomography Source: Eur Respir J 2005; 26: Suppl. 49, 312s Year: 2005
The role of positron emission tomography with 18F-2-fluoro-2-deoxy-D-glucose in respiratory oncology Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-34-0, page=245 Year: 2004
Lung positron emission tomography with FDG in patients with haematological malignancies and acute respiratory failure Source: Eur Respir J 2016; 47: 324-327 Year: 2016